95 related articles for article (PubMed ID: 22690824)
1. Efficacy and ocular surface tolerability of preservative-free tafluprost 0.0015%: a 6-month, single-blind, observational study on naïve ocular hypertension or glaucoma patients.
Rossi GC; Pasinetti GM; Raimondi M; Ricciardelli G; Scudeller L; Blini M; Amisano A; Bianchi PE
Expert Opin Drug Saf; 2012 Jul; 11(4):519-25. PubMed ID: 22690824
[TBL] [Abstract][Full Text] [Related]
2. IOP-lowering efficacy and tolerability of preservative-free tafluprost 0.0015% among patients with ocular hypertension or glaucoma.
Hommer A; Mohammed Ramez O; Burchert M; Kimmich F
Curr Med Res Opin; 2010 Aug; 26(8):1905-13. PubMed ID: 20553122
[TBL] [Abstract][Full Text] [Related]
3. Preservative-free tafluprost 0.0015% in the treatment of patients with glaucoma and ocular hypertension.
Erb C; Lanzl I; Seidova SF; Kimmich F
Adv Ther; 2011 Jul; 28(7):575-85. PubMed ID: 21725844
[TBL] [Abstract][Full Text] [Related]
4. Randomized clinical trial of the efficacy and safety of preservative-free tafluprost and timolol in patients with open-angle glaucoma or ocular hypertension.
Chabi A; Varma R; Tsai JC; Lupinacci R; Pigeon J; Baranak C; Noble L; Lines C; Ho TW
Am J Ophthalmol; 2012 Jun; 153(6):1187-96. PubMed ID: 22310086
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of tafluprost 0.0015% versus latanoprost 0.005% eye drops in open-angle glaucoma and ocular hypertension: 24-month results of a randomized, double-masked phase III study.
Uusitalo H; Pillunat LE; Ropo A;
Acta Ophthalmol; 2010 Feb; 88(1):12-9. PubMed ID: 20420586
[TBL] [Abstract][Full Text] [Related]
6. Switching from a preserved to a preservative-free prostaglandin preparation in topical glaucoma medication.
Uusitalo H; Chen E; Pfeiffer N; Brignole-Baudouin F; Kaarniranta K; Leino M; Puska P; Palmgren E; Hamacher T; Hofmann G; Petzold G; Richter U; Riedel T; Winter M; Ropo A
Acta Ophthalmol; 2010 May; 88(3):329-36. PubMed ID: 20546237
[TBL] [Abstract][Full Text] [Related]
7. Spanish multicenter tafluprost tolerability study.
Milla E; Stirbu O; Rey A; Duch S; Buchacra O; Robles A; Navarro C; Gil R; Cordero JM
Br J Ophthalmol; 2012 Jun; 96(6):826-31. PubMed ID: 22399693
[TBL] [Abstract][Full Text] [Related]
8. Effect of preservative-free tafluprost on keratocytes, sub-basal nerves, and endothelium: a single-blind one-year confocal study on naïve or treated glaucoma and hypertensive patients versus a control group.
Rossi GC; Blini M; Scudeller L; Ricciardelli G; Depolo L; Amisano A; Bossolesi L; Pasinetti GM; Bianchi PE
J Ocul Pharmacol Ther; 2013 Nov; 29(9):821-5. PubMed ID: 23944905
[TBL] [Abstract][Full Text] [Related]
9. Tafluprost: a novel prostaglandin analog for treatment of glaucoma.
Pantcheva MB; Seibold LK; Awadallah NS; Kahook MY
Adv Ther; 2011 Sep; 28(9):707-15. PubMed ID: 21858491
[TBL] [Abstract][Full Text] [Related]
10. [Efficacy and tolerability of preservative-free tafluprost 0.0015 % in the treatment of glaucoma and ocular hypertension].
Karhanová M; Mlčák P; Fryšák Z; Marešová K
Cesk Slov Oftalmol; 2012 Oct; 68(4):150-5. PubMed ID: 23214487
[TBL] [Abstract][Full Text] [Related]
11. Switching from latanoprost to fixed-combination latanoprost-timolol: a 21-day, randomized, double-masked, active-control study in patients with glaucoma and ocular hypertension.
Olander K; Zimmerman TJ; Downes N; Schoenfelder J;
Clin Ther; 2004 Oct; 26(10):1619-29. PubMed ID: 15598478
[TBL] [Abstract][Full Text] [Related]
12. [Efficacy and safety of long-acting carteolol 1% once daily. A double-masked, randomized study].
Trinquand C; Romanet JP; Nordmann JP; Allaire C;
J Fr Ophtalmol; 2003 Feb; 26(2):131-6. PubMed ID: 12660585
[TBL] [Abstract][Full Text] [Related]
13. Short-term tolerability of once-daily timolol hemihydrate 0.5%, timolol maleate in sorbate 0.5%, and generic timolol maleate gel-forming solution 0.5% in glaucoma and/or ocular hypertension: a prospective, randomized, double-masked, active-controlled, three-period crossover pilot study.
Sonty S; Mundorf TK; Stewart JA; Stewart WC
Clin Ther; 2009 Oct; 31(10):2063-71. PubMed ID: 19922877
[TBL] [Abstract][Full Text] [Related]
14. Long-term efficacy and safety of bimatoprost for intraocular pressure lowering in glaucoma and ocular hypertension: year 4.
Williams RD; Cohen JS; Gross RL; Liu CC; Safyan E; Batoosingh AL;
Br J Ophthalmol; 2008 Oct; 92(10):1387-92. PubMed ID: 18621791
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety levels of preserved and preservative-free tafluprost are equivalent in patients with glaucoma or ocular hypertension: results from a pharmacodynamics analysis.
Hamacher T; Airaksinen J; Saarela V; Liinamaa MJ; Richter U; Ropo A
Acta Ophthalmol Suppl (Oxf ); 2008; 242():14-9. PubMed ID: 18752510
[TBL] [Abstract][Full Text] [Related]
16. Prospective Observational Post-Marketing Study of Tafluprost for Glaucoma and Ocular Hypertension: Effectiveness and Treatment Persistence.
Kuwayama Y; Hashimoto M; Kakegawa R; Nomura A; Shimada F
Adv Ther; 2017 Jun; 34(6):1411-1425. PubMed ID: 28502035
[TBL] [Abstract][Full Text] [Related]
17. Long-term effect of BAK-free travoprost on ocular surface and intraocular pressure in glaucoma patients after transition from latanoprost.
Aihara M; Otani S; Kozaki J; Unoki K; Takeuchi M; Minami K; Miyata K
J Glaucoma; 2012 Jan; 21(1):60-4. PubMed ID: 21278589
[TBL] [Abstract][Full Text] [Related]
18. Prospective observational post-marketing study of tafluprost for glaucoma and ocular hypertension: short-term efficacy and safety.
Kuwayama Y; Nomura A
Adv Ther; 2014 Apr; 31(4):461-71. PubMed ID: 24615289
[TBL] [Abstract][Full Text] [Related]
19. A 6-week, double-masked, parallel-group study of the efficacy and safety of travoprost 0.004% compared with latanoprost 0:005%/timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension.
Franks WA; Renard JP; Cunliffe IA; Rojanapongpun P
Clin Ther; 2006 Mar; 28(3):332-9. PubMed ID: 16750448
[TBL] [Abstract][Full Text] [Related]
20. A randomized, 36-month, post-marketing efficacy and tolerability study in Sweden and Finland of latanoprost versus non-prostaglandin therapy in patients with glaucoma or ocular hypertension.
Friström B; Uusitalo H
Acta Ophthalmol; 2010 Feb; 88(1):37-43. PubMed ID: 19900212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
